Press release

Press release

March 25, 2021

Follicum appoints new CEO and establishes new role as Chief Scientific Officer

Follicum AB announces today that the company has recruited Dr. Kim Arvid Nielsen as new CEO, taking office on April 6, 2021. He has extensive experience in business development, investor relations and drug development from leading positions in both small and large pharmaceutical companies. At the same time, Follicum is establishing a new position as […]

March 23, 2021

New preclincial study confirms mechanism of action of Follicum’s novel tissue repair peptides

Follicum AB today announces that significant progress has been made in the company’s development of new drug treatments for diabetes and other diseases. Within the framework of a preclinical research project, the interaction between one of Follicum’s tissue-repairing peptide families and a specific receptor has been characterized in detail. This will help accelerate continued optimization […]

October 29, 2020

Follicum carries out a directed share issue of approximately SEK 36.6 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, BE SUBJECT TO LEGAL RESTRICTIONS OR WOULD REQUIRE REGISTRATION OR OTHER […]

June 22, 2020

Follicum AB receives Notice of Allowance from the US Patent Office for the protection of the company’s peptides developed for the treatment of diabetes and its related complications

Follicum AB (“Follicum”) has received information that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance of the US patent application 16/666,960. The patent application covers the company’s peptides and their use for treatment of diabetes and diabetes-associated complications. The application is directed to new peptides from the company’s two […]

June 3, 2020

Follicum re-starts phase II study with FOL-005 for stimulation of hair growth and expands the number of study centres

Follicum AB (“Follicum” or the “company”) today announced that the clinical Phase IIa study with a cream-like formulation of FOL-005 will re-start, following a pause due to the Covid-19 pandemic. To increase the recruitment rate, a third study centre has been contracted. The study comprises approximately 200 male patients with hair loss who are treated […]